Trial Profile
A phase 2 multi-center, open label long-term extension trial to assess the safety of oral UK-390 957 administered as required in adult men with premature ejaculation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2012
Price :
$35
*
At a glance
- Drugs UK 390957 (Primary)
- Indications Premature ejaculation
- Focus Adverse reactions
- Sponsors Pfizer
- 11 Dec 2005 New trial record.